InvestorsHub Logo
icon url

Blane

05/18/20 10:52 AM

#78644 RE: JA2626 #78638

1). The comparison trial will settle the argument as well as see if remdesivir truly has any true utility.

2). The trail places Cytodyn on center stage with other major players. A very shrew move by NP.

3). It demonstrates how much confidence the management team has in the efficacy of Leronlimab.

4). It places Leronlimab itself center stage for when it demonstrates overwhelmingly superior effects over remdesivir.

5). I personally believe this is a formality. This is the ultimate showdown, and we all know Leronlimab is going to win. This just lets the world see the fight. Ding Ding!